Affordable Access

deepdyve-link
Publisher Website

Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.

Authors
  • Schor, Stanford1
  • Einav, Shirit1
  • 1 Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, School of Medicine, Stanford University , 300 Pasteur Drive, Lane Building Rm L127, Stanford, California 94305, United States. , (United States)
Type
Published Article
Journal
ACS Infectious Diseases
Publisher
American Chemical Society
Publication Date
Feb 09, 2018
Volume
4
Issue
2
Pages
88–92
Identifiers
DOI: 10.1021/acsinfecdis.7b00268
PMID: 29298032
Source
Medline
Language
English
License
Unknown

Abstract

There is a large, global unmet need for the development of countermeasures to combat intracellular pathogens. The development of novel antimicrobials is expensive and slow and typically focuses on selective inhibition of proteins encoded by a single pathogen, thereby providing a narrow spectrum of coverage. The repurposing of approved drugs targeting host functions required for microbial infections represents a promising alternative. This review summarizes progress and challenges in the repurposing of approved drugs as host-targeted broad-spectrum agents for the treatment of intracellular pathogens. These strategies include targeting both cellular factors required for infection by various viruses, intracellular bacteria, and/or protozoa as well as factors that modulate the host immune response to these microbial infections. The repurposed approach offers complementary means to develop therapeutics against existing and emerging intracellular microbial threats.

Report this publication

Statistics

Seen <100 times